HALO News and Press, Halozyme Therapeutics Inc. From 03/28/24

2024-03-28 13:11:15 ET More on Xeris Pharmaceuticals Xeris Biopharma (XERS) Q4 2023 Earnings Call Transcript Xeris Biopharma: Speculative Buy, Size Your Position Accordingly Xeris Biopharma Holdings Stock Is A Hold With Robust Performance Into 2024 Xeris Phar...

2024-03-21 07:00:09 ET More on Argenx SE argenx SE (ARGX) Q4 2023 Earnings Call Transcript argenx: Upgrading To 'Strong Buy' On Vyvgart's Q4 Sales, Empasiprubart Data, Pipeline Expansion Argenx SE GAAP EPS of -$1.68 misses by $0.30, revenue of $374M beats by $10.28M ...

2024-03-13 14:25:31 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips While the technology sector has been enjoying ridiculous returns, it’s inevitable that a slowdown (or even a correction) may materialize, which brings to the table biotech stocks . T...

2024-02-21 07:30:02 ET JMP Securities analyst issues UNDERPERFORM recommendation for HALO on February 21, 2024 07:00AM ET. The previous analyst recommendation was Underperform. HALO was trading at $36 at issue of the analyst recommendation. The overall analyst consensus ...

2024-02-21 07:30:02 ET Morgan Stanley analyst issues MARKET OUTPERFORM recommendation for HALO on February 21, 2024 07:00AM ET. The previous analyst recommendation was Market Outperform. HALO was trading at $36 at issue of the analyst recommendation. The overall analyst ...

2024-02-20 20:04:10 ET Halozyme Therapeutics, Inc. (HALO) Q4 2023 Earnings Conference Call February 20, 2024, 04:30 PM ET Company Participants Tram Bui - VP, IR and Corporate Communications Helen Torley - President and CEO Nicole LaBrosse - CFO Conference C...

2024-02-20 16:02:47 ET More on Halozyme Therapeutics Halozyme Therapeutics: A Reasonable Value In An Overvalued Market Halozyme Therapeutics Q4 2023 Earnings Preview EU okays Takeda's Hyqvia co-formulated with Halozyme's Enhanze Seeking Alpha’s Quant R...

HALOZYME REPORTS FOURTH QUARTER AND FULL YEAR 2023 FINANCIAL AND OPERATING RESULTS PR Newswire Reiterating 2024 Financial Guidance: Total Revenue of $915 -985 Million, Representing YOY Growth of 10-19%, Adjusted EBITDA of $535 -585 Million, Representing YOY Growth of 2...

Kajima Corporation ADR (KAJMY) is expected to report for quarter end 2023-12-31 FaZe Holdings Inc. (FAZE) is expected to report for Q4 2023 BrewBilt MFG Inc (BBRW) is expected to report for Q4 2023 Correlate Energy Corp. (CIPI) is expected to report for Q4 2023 Hyzon Motors Inc. (...

2024-02-16 17:20:16 ET More on Halozyme Therapeutics Halozyme Therapeutics: A Reasonable Value In An Overvalued Market EU okays Takeda's Hyqvia co-formulated with Halozyme's Enhanze Halozyme’s early 2023 results indicate a mixed performance Seeking Alp...